膀胱肿瘤抗原检测在浅表性膀胱癌中的初步评估
Initial evaluation of the bladder tumor antigen test in superficial bladder cancer.
作者信息
D'Hallewin M A, Baert L
机构信息
Department of Urology, St. Pieter University Hospital, Catholic University of Leuven, Belgium.
出版信息
J Urol. 1996 Feb;155(2):475-6.
PURPOSE
We analyzed the value of the Bard bladder tumor antigen (BTA*) test for the diagnosis of stage Ta superficial bladder cancer and carcinoma in situ, and compared it to the highly sensitive bladder washing cytology.
MATERIALS AND METHODS
The BTA test is a latex agglutination test that qualitatively detects the presence of basement membrane complexes in the urine. A total of 60 patients with superficial bladder cancer underwent voided urine BTA analysis and bladder washing cytologies.
RESULTS
Of the patients 65% were correctly diagnosed with the BTA test compared to 32% with bladder washings, which is statistically significant (p < 0.001).
CONCLUSIONS
The BTA test is a noninvasive diagnostic tool that is superior to bladder washing cytology for diagnosing superficial bladder cancer.
目的
我们分析了巴德膀胱肿瘤抗原（BTA*）检测对Ta期浅表性膀胱癌及原位癌诊断的价值，并将其与高敏感性的膀胱冲洗细胞学检查进行比较。
材料与方法
BTA检测是一种乳胶凝集试验，可定性检测尿液中基底膜复合物的存在。共有60例浅表性膀胱癌患者接受了晨尿BTA分析和膀胱冲洗细胞学检查。
结果
BTA检测对患者的正确诊断率为65%，而膀胱冲洗细胞学检查为32%，差异具有统计学意义（p < 0.001）。
结论
BTA检测是一种非侵入性诊断工具，在诊断浅表性膀胱癌方面优于膀胱冲洗细胞学检查。
Zotero 插件